Intelligent Scopes, a Claritas HealthTech Subsidiary, Takes Charge of Global Deployment for CystoSmart™ AI Diagnostic Software in Bladder Cancer Detection

13 November 2023 | Monday | News

Claritas HealthTech (Claritas), announces that its subsidiary, Intelligent Scopes Corp (ISC), a USA headquartered company focusing on research, development, and delivery of AI-assisted diagnostic solutions for endoscopy in urology and gastroenterology, will lead the worldwide delivery and deployment of CystoSmart™, an AI diagnostic tool for bladder cancer detection.
Image Source | Public Domain

Image Source | Public Domain

Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in endoscopic and cystoscopic images.

CystoSmart™, is an image enhancement and AI diagnostic tool for bladder cancer detection developed by Claritas through a research collaboration agreement with Khoo Teck Puat Hospital (KTPH) Singapore, with support from Singapore’s National Healthcare Group (NHG)’s Centre for Medical Technologies and Innovations (CMTi).

Bladder cancer is the 10th most common cancer in the world, and the 6th most common in men. Diagnostics using cystoscopes for examination of the bladder is challenging, and time and resource intensive. CystoSmart™, an innovative solution with superior detection rates is currently under FDA review for clearance.

Dr Laszlo Neumann, CTO of Claritas commented, “We are excited to be working with the clinical team from Singapore in developing CystoSmart™. Our joint objective has been to develop a precision AI tool that can be used as an aid by clinicians to significantly improve patient care.”

Dr. Siying Yeow, clinical principal investigator for CystoSmart™ and consultant urologist at KTPH commented, “We are very pleased to see the progress we have made with Claritas in developing CystoSmart™. Our aim has been to develop an AI diagnostic tool that enhances the accuracy of detection of bladder cancers. CystoSmart™ will be beneficial in enabling appropriate treatment for newly diagnosed cancers, the accurate recognition of tumor recurrences, and complete tumor resection during surgery.”

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in